Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) and citalopram are not known to have a direct pharmacokinetic interaction that would make the combination unsafe, but there are two things worth understanding before you take them together: how semaglutide slows gastric emptying, and what that can mean for the absorption of oral medicines. Both are prescription-only medicines requiring individual clinical assessment, so a prescriber who can see your full medication list is always the right starting point. Semaglutide's mechanism is central to understanding why this question comes up at all.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Summary of Product Characteristics for semaglutide, published on the electronic Medicines Compendium, notes that because the medicine delays gastric emptying, it has the potential to influence the absorption of orally administered drugs. This is not unique to Wegovy, it is a class effect of GLP-1 receptor agonists. In the clinical pharmacology studies conducted before licensing, semaglutide did not meaningfully alter the bioavailability of most tested oral medicines. Citalopram was not among the specifically studied drugs in those studies, so there is no published data showing a clinically significant absorption interaction. The practical implication is that the combination is not contraindicated in prescribing guidance, but it also has not been exhaustively tested in a head-to-head study. A prescriber reviewing your full medication history is best placed to weigh that gap against your individual circumstances. For context on the wider list of medicines that warrant more careful thought alongside semaglutide, the full drug interaction picture for Wegovy covers the areas where caution is formalised in the guidance.
One concern that circulates online is that citalopram raises the risk of a prolonged QTc interval, and that combining it with Wegovy compounds that risk. It is worth addressing directly: citalopram does carry a dose-dependent QTc warning, which is why the Medicines and Healthcare products Regulatory Agency updated citalopram's prescribing information some years ago and the maximum daily dose in many adults is now 40 mg. Semaglutide's product information does not list QTc prolongation as a known effect, so the two medicines are not additive on that measure in the way that, for example, two QTc-prolonging antiarrhythmics would be. That said, if you are on higher-dose citalopram, have a history of cardiac arrhythmia, or take other medicines that affect cardiac conduction, your prescriber needs to know before starting Wegovy. The medicines to avoid with semaglutide page explains the categories where interaction risk is more formally established.
There is a separate, broader point worth raising here. Wegovy's active ingredient and pharmacology primarily targets appetite and metabolism, but GLP-1 receptors are present in the brain as well as the gut, and the research on mood effects is still developing. Current UK prescribing guidance does not list depression or anxiety as a contraindication to semaglutide, nor does it flag a specific interaction with SSRIs. However, the MHRA's Yellow Card scheme remains the mechanism by which unexpected signals (including any new psychiatric symptoms noticed after starting a GLP-1 medicine) are collected and reviewed. If you are stable on citalopram and notice any change in mood after starting Wegovy, that is worth raising promptly with your prescriber rather than attributing it to one cause or the other. You can also report unexpected effects directly at the MHRA Yellow Card service. The NHS medicines page on semaglutide lists the known side-effect profile as assessed at licensing and is a reliable reference point for patients.
If you are already taking citalopram and are considering Wegovy for weight management, the most important step is straightforward: list every medicine, including over-the-counter and herbal products, on your consultation form. A GPhC-registered Independent Prescriber reviews each consultation, every submission is read by a real clinician, not processed automatically. That review is where potential interactions, your cardiac history, and any relevant mental health background are factored in. If the prescriber has questions or needs to liaise with your GP, that happens before any prescription is issued. You might also find it useful to read about semaglutide alongside propranolol, since propranolol raises a related but different set of interaction considerations. On the question of cost, a clear explanation of what Wegovy costs through a private clinic may help you plan. When you are ready to discuss your personal medication list with our clinical team, you can start your free consultation and have that conversation with a prescriber the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.